-
Typhoon Dujuan leaves four dead in Japan, 45,000 houses without power
-
Swimming prodigy Yu, 13, says 'interviews way harder than racing'
-
G7 leaders condemn Houthi strikes on Saudi Arabia
-
Star coaches make their bows as Nations League returns
-
Google data centre sparks protests in Austria
-
Rams bounce back as Giants reel from Dart injury
-
Shin Ohashi: Junk food-loving teen and Japan's next big swimming hope
-
In Bangladesh, Pakistan's Jinnah photo stirs anger
-
Stocks rise on AI buzz, drop in oil prices
-
Two New Zealand naval ships transit Taiwan Strait
-
China's robot dancers limber up for America's Got Talent final
-
Zidane gets down to work as France start new era
-
Despite military might, Saudi struggles to crush the Houthis
-
Inside the Venezuelan prison meant to 'drive you insane'
-
Trump to tout deals, defend Iran war in UN speech
-
UK king braces as memoir by Diana's brother goes on sale
-
Sri Lanka to issue verdict in landmark Easter attack trial
-
No green light to lift EU sanctions on Russian oligarchs, talks to resume
-
Macron says talks with Trump on Red Sea, Ukraine 'constructive'
-
UK agrees support for Saudi in struggle with Houthis: reports
-
Green policies just good politics, says UK minister
-
EU foreign policy chief calls for continued sanctions on Russia
-
Bardot auction in Paris fetches nearly one million euros
-
Flights scrapped, evacuations urged as Typhoon Dujuan wallops Japan
-
No timeline on Daniels injury return, says Commanders coach
-
Fonseca to take break from tennis
-
British Columbia sues OpenAI in US court over Canada school shooting
-
A Cuban zoo, and its animals, in epic battle for survival
-
French star Batum retires after 18-year NBA career
-
Infantino proposes consulting federations to reform FIFA
-
Zidane leads first France training session
-
El Nino weather pattern enters record territory: scientist
-
Man shot by ICE agent in Texas detained with bullet inside him: lawyer
-
OpenAI calls for US to lead global effort on AI standards
-
California declares state of emergency ahead of El Nino
-
South African ostriches plucked alive for luxury fashion: report
-
South Africa arrests three more suspects, after nine women murdered
-
US networks halt Trump coverage in revolt over White House ban
-
Carse needs time away from England, says captain Brook
-
Paramount settles with US states to clear Warner Bros. mega-merger
-
NOWPayments Releases Cross-Chain Payout Data Revealing Key Performance Benchmarks Across TRON, BNB Chain, and Solana
-
Climate crisis a job for world leaders, not just activists: UK FM
-
British Museum bans photos of Bayeux Tapestry as crowds linger
-
US networks halt Trump coverage over White House ban
-
COP31 host says AI climate footprint to be a summit priority
-
French singer accuses Miley Cyrus of plagiarism
-
Berlin's far-left vote winners reject anti-semitism charges
-
EU fines Google 403 mn euros for location data breach
-
Mancini eager for 'new adventure' on Italy return
-
'Best is yet to come,' says De la Fuente after Spain extension
Ketamine pill treats depression without psychedelic effects: study
A new pill that slowly releases ketamine could treat people with severe depression without giving them the psychedelic side effects of the often-misused drug, early trial results suggested on Monday.
First developed in the 1960s as an anaesthetic, ketamine's hallucinogenic and dissociative effects led to it becoming a party drug dubbed "Special K".
However, mounting research has demonstrated that ketamine is effective for the roughly quarter of people suffering from depression who see little benefit from common anti-depressant drugs.
In many countries, ketamine has been prescribed for depression for years.
US billionaire Elon Musk told CNN in March that he regularly uses a small amount of prescribed ketamine because it is "helpful for getting one out of the negative frame of mind".
The drug has long been administered intravenously in clinics, but more recently a nasal spray using a derivative called esketamine has increased in popularity.
Both can cause patients to have side effects such as dissociation, high blood pressure and an elevated heart rate.
There are also fears that medical use of the drug could slide into abuse.
The pill described in the journal Nature Medicine on Monday takes more than 10 hours to break down in the liver, lead study author Paul Glue told AFP.
"The really interesting feedback from patients is the lack of side effects -- no euphoria, no dissociation," said the researcher at New Zealand's University of Otago.
"I don't think these tablets would appeal to people who are abusing ketamine."
- Electro-shock alternative -
The phase 2 trial involved more than 270 people with depression who had previously tried an average of four different anti-depressant drugs.
More than half taking the ketamine pill went into remission for their depression, while 70 percent of the placebo group relapsed after 13 weeks, the study said.
Julaine Allan, an expert on mental health and addiction at Australia's Charles Sturt University who was not involved in the study, praised the trial while emphasising that more research is needed.
Ketamine does not work for everyone, and the "positive effects may wear off over time," she told AFP.
Michel Hoffmann, a psychiatrist at Geneva University Hospitals, said there is "real enthusiasm" in the medical community for ketamine's potential for treating depression.
"For patients who don't respond to conventional drugs, ketamine offers a way to avoid electro-shock therapy," he told AFP.
This last-resort treatment, which involves sending electric currents through the brain, has been proven to be effective.
But it can cause memory loss -- and some patients fear the procedure after seeing depictions of it in films such as "One Flew Over the Cuckoo's Nest".
- Fears of 'opioid style crisis' -
Some psychiatrists remain hesitant to prescribe ketamine for depression, fearing their patients could end up misusing the drug.
Last year, "Friends" actor Matthew Perry became the latest high-profile death from a ketamine overdose.
US police are investigating how Perry obtained the doses that caused his death -- he had reportedly not had a supervised infusion session for several days.
One potential benefit of quick-acting ketamine seen in previous research is that it could help patients considering suicide.
But there is "the plausible concern that the widespread use of ketamine might trigger a new opioid style crisis," Oxford researcher Riccardo De Giorgi said in a 2022 BMJ editorial.
By ridding ketamine of the side effects sought by some partygoers, the slow-release pill could alleviate some of these concerns.
There were still some side effects from the pill, the most common being headaches, dizziness and anxiety.
More research including phase 3 trials is needed before the drug can be reviewed by national medicine agencies, meaning it will be at least two or three years before patients could potentially access the pills, Glue said.
D.Schlegel--VB